Clinical Trial Update: PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2 [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating PS-341 (bortezomib) in combination with trastuzumab (Herceptin) in HER-2 overexpressing, stage IV breast cancer; the study has been com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• PS-341 (bortezomib)

Snippet

Sponsor: Jules Bordet Institute | Conditions: Carcinoma Breast Stage IV | Phase 1 | Status: COMPLETED